Immunic AG is headquartered in Germany from where overseeing an expansion to Australia to conduct clinical trials was daunting. We explain how Acclime supported Immunic’s Australia market entry.
Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic AG in Germany wanted to expand to Australia and undertake clinical trials.
Immunic was interested in conducting clinical trials in Australia, but they needed support to manage this expansion and to administer an Australian subsidiary in line with local tax regulations and law. They also needed guidance to find key local partners to get their clinical trial up and running.
Acclime was recommended to us by several German biotech companies. We have been very pleased with how easy they have made it to estabish and administer our Australian subsidiary.
The whole process has run smoothly. Our Phase 1 trials commenced successfully late in 2019, and we look forward to working with CoSec into the future.
Erika von der Decken